sublingual nitroglycerin. This presentation was assumed as coronary vasospasm, and beta-blockers were discontinued while therapy with long-acting nitrates and calcium-channel blockers was started. After therapeutic optimization there were no recurring episodes of chest pain, and the patient's subsequent hospitalization was uneventful. She was discharged still maintaining a mildly reduced EF as well as hypocontractility of all LV distal segments. At follow-up the patient did not experience new episodes of chest pain and had a complete reversion of ECG repolarization changes (Fig. 3C) , as well as presenting with a normal LVEF and no significant wall motion abnormalities.
Although clinical insight into TTS has greatly expanded over the years, its specific mechanism remains controversial. 4 One of the most established and unifying hypothesis pertains to sympathetic nervous system derangement and subsequent catecholaminergic imbalances. 6, 7 The possible overlap between TTS and coronary vasospasm has been highlighted in the contemporary literature, although the specific nature of a possible relationship still warrants further ascertainment.
1,2,8-10 As described in this case report, and in accordance with the current guidelines, the presence of both these entities can have therapeutic importance. 1, 11 In TTS, the possible role of cathecolamine-induced cardiac damage is highlighted in the current European Society of Cardiology position paper, where avoidance of inotropes (such as noradrenaline and adrenaline) should be considered, 1 as this could further worsen the patient's clinical status. 1, 12 On the other hand, in patients with reduced LVEF (such as the case presented), beta-blockade should be considered. 1 Given the high likelihood of coronary vasospasm in this case, and the possible adverse effects of betablockers in this setting, 9 this therapy was discontinued, with the patient having no more chest pain episodes after further optimization. This case report highlights the presence of coronary vasospasm in a patient with concurrent TTS. Given the important considerations in terms of both diagnosis and treatment, the nature of the association between these two entities, as well as the role of specific therapeutic agents, should be the focus of further research, given its clinical importance.
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The Editor, We read the interesting article 'The truth about artificial sweeteners -are they good for diabetes' by Purohit and Mishra 1 published in your esteemed journal. This paper brings out clearly and convincingly side effects associated with currently popular sweeteners namely saccharin, aspartame, neotame and sucralose particularly their cancer producing potentials. On the other hand, there is a brief mention about stevia which is derived from plant Stevia rebaudiana. It possesses unique property of not only having a sweet taste but also sugar lowering and lipid lowering property -a distinct advantage over chemical sweeteners.
2 Stevia rebaudiana contains steviol glycosides namely steviosides, rebaudioside, steviolbioside and isosteviol, which are responsible for its sweetness and sugar lowering properties. It has been said to be safe in long term use. 3 Interestingly while stevia is a safe sweetener the currently popular chemical sweeteners have potential to cause cancer when used for long time. It is also well known that these sweeteners are used in many smokeless tobacco products like gutkha and paan masala preparations and these patients are reported to have oral and bladder carcinoma. 4 Further looking at the current pandemic of diabetes prevailing all over Indian subcontinent, use of stevia as an alternative sweetening agent for people who have diabetes, pre-diabetes and/or obesity needs to be explored in robust statistically designed studies.
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